Company / Capital Expenditures
TScan Therapeutics, Inc. Capital Expenditures History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$3.8M
FY2025
5-year range
$3.1M / $9.9M
FY2021-FY2025
Trend
+21.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $4M.
Based on SEC 10-K filings.
$4M in FY2025 with a 3-year CAGR of -27.3%.
Declined from $4M to $4M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -27.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -27.3%, indicating a declining trend.
- In FY2025, capital expenditures increased 21.6% year-over-year.
- Peak capital expenditures was recorded in FY2022.
- Lowest capital expenditures in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.8M | +21.6% |
| FY2024 | $3.1M | -25.5% |
| FY2023 | $4.2M | -57.5% |
| FY2022 | $9.9M | +134.6% |
| FY2021 | $4.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026